Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin receptor (SSR) analogs is now an established systemic treatment for neuroendocrine tumors (NET). However, more short- and long-term data about renal and hepatotoxicity is needed. Here we present our experience in...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Heying, Ferri, Valentina, Fisher, George Albert, Shaheen, Shagufta, Davidzon, Guido Alejandro, Iagaru, Andrei, Mari Aparici, Carina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177120/
https://www.ncbi.nlm.nih.gov/pubmed/35641196
http://dx.doi.org/10.1093/oncolo/oyab072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177120/
https://www.ncbi.nlm.nih.gov/pubmed/35641196
http://dx.doi.org/10.1093/oncolo/oyab072

Ejemplares similares